A nucleic acid amplification procedure, the polymerase chain reaction (PCR), has been used to establish a diagnostic assay for the identification of cytomegalovirus (CMV) immediateearly sequences in clinical specimens. Preliminary testing against virus-infected cell cultures indicated that the PCR assay was highly CMV-specific, recognizing both wild-type and laboratory strains of CMV. There was no cross-reactivity with human DNA or with DNA from other herpes viruses. The sensitivity of the assay, using cloned CMV AD169 Eco RI fragment-J as template, was 1 viral genome per 40,000 cells. In a prospective study of CMV infection in bone marrow transplant recipients, the PCR assay correctly identified four patients with confirmed CMV infection. In three of these patients who were followed longitudinally, correlation of DNA reactivity with CMV culture and CMV antibody status over time indicated that DNA was the most sensitive marker for the diagnosis of CMV infection.
Introduction
Cytomegalovirus (CMV)' infections are a major cause of illness and death in immunocompromised patients (1, 2) . As many as 25% of allogeneic bone marrow transplant (BMT) recipients die of disseminated CMV disease with interstitial pneumonitis (IP) (3) . Rapid diagnosis and early treatment form the basis for the effective clinical management of these patients.
Currently most diagnoses depend on a rise in anti-CMV antibody titer or on the direct isolation of CMV from infected tissues. Neither procedure is satisfactory. Antibody responses are often delayed or completely absent in immunosuppressed marrow recipients (4) and recovery of CMV in culture can take up to 6 wk to obtain a definitive result (5) .
Recently it has been shown that the rapidity of CMV diagnosis can be increased using either MAb to demonstrate the presence of viral antigens (6) or DNA probes to detect viral nucleic acid (7) (8) (9) . The major drawbacks of these technologies have been their lack of sensitivity when compared with conventional culture methods (10, 1 1) and, in the case of DNA, the frequent hybridization of probes with bacterial sequences found in nonsterile specimens (12, 13) .
To circumvent these problems and facilitate the diagnosis of CMV disease, we have used an in vitro gene amplification technique to increase both the sensitivity and specificity of CMV DNA detection. The technique, known as the polymerase chain reaction (PCR), uses synthetic oligonucleotide primers and DNA polymerase to enzymatically amplify selected DNA target sequences, up to several million-fold in 2 h (14) . PCR amplification has been successfully applied to the diagnosis of sickle cell anemia (15) , hemophilia (16) , human papilloma virus (17) , HIV-1 (18, 19) , and the human T cell lymphoma/leukemia virus (20) . We report the adaptation of PCR technology to the identification of CMV DNA in blood, urine, saliva, and lung tissue and we describe our preliminary experience using this technology to longitudinally monitor CMV infections in BMT recipients. To evaluate the efficacy of PCR testing we have correlated CMV DNA patterns over time with clinical outcome and with CMV serology and the ability to isolate CMV in culture.
Methods
Patients and specimen collection. Seven allogeneic BMT recipients receiving their transplants at the Foothills Hospital, Calgary, AB, were longitudinally sampled pretransplant and on several occasions (up to 10 times) posttransplant. An eighth BMT recipient, a patient at the Montreal General Hospital, was sampled on two occasions only. Serum was collected for antibody studies; urine, saliva, and blood for CMV DNA studies. An 
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HSV-I and HSV-II were provided by the Alberta Provincial Laboratory. The presence of CMV in wild-type strains was confirmed by indirect immunofluorescence using an MAb against the 72,000-D early nuclear protein (1 1).
Isolation of DNA. The methods used for DNA extraction from virus-infected cell cultures, whole blood, PMN-and mononuclearenriched blood fractions have been described previously (22, 23) . For studies of CMV excretion, 12 ml of urine or saliva (collected in saline) were centrifuged for 1 h at 38,000 rpm (180,000 g) in an SW-41 rotor in a centrifuge (Beckman Instruments, Inc., Palo Alto, CA). The concentrated viral pellets were then lysed and DNA was extracted (22 (24, 25) and it has no reported homology with human DNA (26, 27) . Synthesis of the primers and probe were performed on a DNA synthesizer (model 380 A; Applied Biosystems, Foster City, CA) using published sequence data (24) and the methoxyphosphoramidite method (28) . The design of the PCR procedure for detection of CMV IE sequences is outlined in Fig. 1 Asg ofcellular DNA (320,000 cells) to give a sensitivity (after 18 h of autoradiographic exposure) of 1 viral genome per 40,500 cells. As outlined in Methods, a selection of these reconstituted specimens was included in each PCR reaction as a measure of intertest variability. Our results showed little or no variation between runs. We consistently detected at least one viral genome per 20,000 cells.
Specificity studies were performed on established cell lines (ATCC) harboring known strains of CMV (AD 169, Davis), HSV-I (F), HSV-II (G and MS), and VZV (Oka, Webster, and Ellen). Additional controls included DNA extracted from EBV-infected B95-8 marmoset cells, as well as 100 pg each of purified HSV virion DNA, pBR322 DNA and Escherichia coli DNA. The high degree of specificity contributed by the PCR amplification procedure was shown by the complete lack of any hybridization signal with amplified HSV, EBV, VZV, pBR322, or E. coli DNAs. Representative results are shown in Fig. 2 A, lanes 1-5. In contrast, strong positive hybridization signals were obtained by the amplification of both Davis and AD 169 strains of CMV (Fig. 3 B, lanes 8 and 9) . Retesting of the same samples gave identical results; negatives were consistently negative and positives were consistently positive.
CMV PCR testing of wild-type strains. Before using PCR for diagnosis, it was necessary to establish whether the assay could identify wild-type strains ofCMV found in clinical specimens. Eight clinical strains, grown from the urines ofdifferent patients, were passaged in human fibroblast cell lines. DNA was extracted and amplified as described. In some studies the infected cells were lysed and analyzed by direct amplification without previous DNA extraction. All eight clinical strains of CMV gave reproducible hybridization signals corresponding to the CMV-specific IE gene amplification product. Fig. 2 A shows representative results for two of these isolates (lanes 6 and 7). Wild-type HSV and VZV, on the other hand, failed to give any detectable hybridization signals in three different PCR runs. Direct CMVPCR testing ofclinical specimens: correlations with clinical disease. A total of 504 specimens were analyzed by CMV PCR: 154 from BMT patients and 350 from healthy asymptomatic blood donors. The results of PCR testing are shown in Table I . Again, many of these samples (both positive and negative) were retested and identical results were obtained.
The incidence of DNA positivity in the BMT population was highest in patients with disseminated CMV disease with IP (78%), intermediate in patients with mild or subclinical CMV infection (64 and 31%), and lowest in BMT patients with no evidence of CMV infection (0%). The strongest hybridization signals were observed with lung samples from two patients with IP ( Fig. 3 A, lanes 2 and 3; Fig. 3 B, lane 1) .
Lesser amounts of CMV DNA were detected in two of three asymptomatic CMV seropositive blood donors. One donor was positive for saliva on one occasion only. The second was positive twice for both saliva and the PMN-enriched cell fraction of peripheral blood. 12 of 13 CMV seronegative posttransplant the patient developed episodic fever and CMV was cultured from urine. This correlated with a significant increase of CMV DNA excretion in saliva, which was sustained throughout the study period. The patient recovered and remained CMV seropositive. CMV DNA was not detected in this patient's blood (data not shown).
Patient 3 (Fig. 3 B lanes 5-7; Fig. 5 ) was an 18-yr-old woman with severe aplastic anemia. She received a BMT in December 1985 from an HLA-DR matched female sibling. Both donor and recipient were CMV IgG/IgM and CMV DNA negative pretransplant. The patient's posttransplant course was unremarkable. At week 11 CMV DNA appeared in her peripheral blood and by week 17 she had seroconverted to CMV IgM antibody positivity. At week 17 CMV DNA was also found in urine. This patient remained asymptomatic and CMV culture negative. CMV DNA was cleared from the peripheral blood by week 28 (Fig. 5) .
The fourth patient (Fig. 3 B, lanes 1-4) Overall comparison ofDNA hybridization and viral culture.
A total of 512 clinical specimens (including the 8 non-BMT urine isolates) were analyzed by both PCR and culture methods. Hybridization and culture yielded concordant results with 456 samples; 441 samples were negative and 15 samples were positive with both test systems. The remaining 56 specimens were DNA hybridization positive but culture negative. 47 of these discrepant samples came from BMT patients with confirmed CMV infection; 5 came from 2 CMV seropositive blood donors, and 4 samples (2 urine and 2 saliva) were taken from a single CMV seronegative blood donor.
Discussion
Rapid diagnosis of CMV can be accomplished by detection of the viral genome (7-1 1) . Most CMV DNA diagnostic assays have involved DNA extraction and dot blot hybridization using recombinant fragments of CMV as probes. These assays have a sensitivity limit of only 1 viral genome per 20 cells (31) . In addition to low sensitivity, conventional dot blot assays are limited by problems inherent in the methodology. Contaminants in the DNA extract can interfere with DNA binding to filters resulting in reduced specific adherence and false negative results. Alternatively, contaminants can result in nonspecific probe trapping and the detection of false positives (12) . Bacteria in clinical specimens can also lead to false positive reactions (i 1, 12) . This problem, the vector homology problem, arises when vector sequences in the recombinant probe hybridize to homologous sequences contained in bacteria of the test specimen. The use of extensively purified viral insert probes and control hybridization with vector DNA is only partially effective in eliminating this problem (9, 13) .
To overcome these problems we have used PCR amplification in combination with oligonucleotide probe hybridization. As in recent studies with HIV-I (18, 19) and human T cell lymphoma/leukemia virus (20) , the amplification step results in a significant increase in the sensitivity of viral DNA detection. In vector homology problem associated with recombinant DNA technology. In preliminary testing we have shown that PCR can reproducibily detect one copy of the CMV IE target sequence in 40,000 cells. This corresponds to a 2,000-fold increase in sensitivity over unamplified DNA assays for the detection of CMV IE sequences (1 1, 31) . The successful amplification of Davis and AD 169 strains, as well as eight ofeight wild-type strains of CMV, indicates that the PCR assay recognizes most, if not all, CMV strains. The ability to identify a wide range of strains was expected since amplification sequences were selected from a highly invariant region of the CMV genome. These sequences are known to be identical in both Towne and AD169 strains (24, 25) . The high specificity of the PCR assay was shown by the complete lack of hybridization with human cellular DNA, E. coli DNA, or DNA from other herpes viruses.
The clinical applicability of the CMV PCR test has been shown in a longitudinal surveillance study of CMV infection in BMT patients. The PCR assay correctly identified four patients with documented CMV infection. Three of these patients were followed longitudinally. In these patients, the appearance of CMV DNA preceded clinical and/or serological evidence ofCMV infection. These results suggest that PCR is a valuable marker for the early stages of CMV infection. Since this work was completed, Loche and Mach (32) The ability ofPCR to identify CMV in the peripheral blood of BMT patients is particularly important since CMV viremia is frequently associated with serious disease (33) . In this study, CMV DNA was identified in peripheral blood of both patients who developed IP. Although the levels of CMV in blood were lower than in lung and urine, we believe this reflects differences in viral titer rather than a lack of sensitivity with blood specimens. This is based on reconstruction experiments and on studies in AIDS patients where high levels of CMV are frequently detected in peripheral blood (unpublished results (34) , using in situ hybridization, were able to detect CMV RNA transcripts in 0.03-2.0% of PBMC in eight of eight asymptomatic seropositive donors. Spector and associates (35), using a dot blot assay, detected CMV in the peripheral blood of 3 of 41 seropositive donors. However, we and others (31, 36) , using similar technology, have been repeatedly unable to identify CMV DNA in blood donors. In the present study, using sensitive PCR methods, we were able to detect CMV in two of three seropositive donors and in 1 of 13 seronegative donors. Patterns of CMV DNA reactivity in individual donors over time showed only intermittent CMV viremia and excretion. This is in contrast to the protracted DNA patterns observed in the BMT population and suggests a low level ofviral activity that is only periodically detectable by hybridization. The detection of CMV DNA in only 2 of 43 (4.7%) of peripheral blood specimens from seropositive donors is consistent with what is known about CMV carrier rates in the donor population. These rates have been estimated to range between 1 and 13% (37) .
There are several possibilities to explain the lack of CMV DNA detection in two seropositive, culture-negative individuals (one donor and one BMT patient). One possibility is that the PCR assay is not sufficiently sensitive to detect the very low levels of virus present in these persons. This possibility could, in theory, be resolved by increasing the number ofPCR amplification cycles. Alternatively, it could indicate that these individuals have been exposed to CMV in the past but that their infection has been successfully resolved. A third possibility is that these individuals harbor strains of CMV that are not detectable by the present PCR assay or that they carry viral genomes that are defective in the IE region. A fourth possibility is that these individuals are temporarily in an inactive (latent) phase and that continued monitoring will eventually result in the detection of positives. The detection of CMV DNA in one CMV seronegative donor is more difficult to explain. We are currently sequencing this amplification product to confirm its identity.
To summarize, our findings suggest that PCR amplification technology is more sensitive than conventional culture methods for the diagnosis of CMV. One of the major advantages of the technology is its applicability to a wide variety of biological specimens. In longitudinal surveillance studies we have shown that DNA testing of multiple tissues can provide additional information on the overall CMV status of BMT patients. It is anticipated that ongoing serial study will eventually lead to the identification of CMV reactivity patterns that are of diagnostic importance. The potential of the PCR assay to detect early CMV, especially CMV viremia, has important implications since early diagnosis may allow physicians to modify antiviral or immunosuppressive regimens in time to alter the course of serious CMV disease.
